<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04973657</url>
  </required_header>
  <id_info>
    <org_study_id>VK0214-102</org_study_id>
    <nct_id>NCT04973657</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN</brief_title>
  <official_title>Phase 1b, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability, PD and PK of VK0214, in Subjects With the Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viking Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viking Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects will be administered multiple doses of VK0214 in a cohort dose escalation process. A&#xD;
      total of up to 36 subjects will be enrolled in the study, into one of three dose cohorts. For&#xD;
      each cohort, up to 12 subjects will be randomized to receive VK0214 or placebo in a 3:1 ratio&#xD;
      so that there will be a total of up to 9 subjects for each of the active doses and up to 3&#xD;
      subjects dosed with placebo in each cohort.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first part of VK0214-102 will include the first 2 dose cohorts and placebo, which will be&#xD;
      dosed in parallel (up to N=24). The first 2 doses used in these cohorts will be 20 mg QD and&#xD;
      40 mg QD for 28 days. A Dose Level Review Team (DLRT) meeting will be held at the end of the&#xD;
      first 2 parallel doses.&#xD;
&#xD;
      The DLRT will review safety, tolerability, and preliminary efficacy data from cohort 1 and 2.&#xD;
      If the data analyzed show that the first 2 doses are safe and well tolerated the DLRT may&#xD;
      make a recommendation for proceeding to commence dosing in the third dose cohort.&#xD;
&#xD;
      Based upon outcomes in Cohorts 1 and 2, the sponsor may decide to include a third dose&#xD;
      cohort. Before screening may be initiated in Cohort 3, data to support dosing in this cohort&#xD;
      will be submitted to the FDA, together with the amended protocol and the dosing&#xD;
      recommendation of the DLRT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious AEs (TESAEs)</measure>
    <time_frame>28 days</time_frame>
    <description>To evaluate the safety and tolerability of multiple oral doses of VK0214 in subjects with AMN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma VLCFAs changes from baseline to day 28</measure>
    <time_frame>28 days</time_frame>
    <description>To evaluate the efficacy of VK0214 on lowering plasma levels of VLCFAs in subjects with AMN</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Pharmacokinetics of VK0214</measure>
    <time_frame>28 days</time_frame>
    <description>Pharmacokinetic profile of VK0214 by measuring Peak Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)</condition>
  <arm_group>
    <arm_group_label>VK0214 Active 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VK0214 Active 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VK0214</intervention_name>
    <description>API in capsule</description>
    <arm_group_label>VK0214 Active 20mg</arm_group_label>
    <arm_group_label>VK0214 Active 40mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>API in capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide a personally signed and dated informed consent document indicating that the&#xD;
             subject has been informed of all pertinent aspects of the study and is willing and&#xD;
             able to participate.&#xD;
&#xD;
          -  Have diagnosis of X-linked adrenoleukodystrophy (X-ALD) by genetic testing and&#xD;
             elevated VLCFAs.&#xD;
&#xD;
          -  Present clinical features of AMN, or adrenal insufficiency.&#xD;
&#xD;
          -  Subjects must be 18 years of age and older.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have the cerebral form of X-ALD, based on medical records, or based on MRI performed&#xD;
             within the last 12 months or MRI at screening&#xD;
&#xD;
          -  Have been treated with any drug targeting TRÎ² or with any drug being tested as therapy&#xD;
             for X-ALD AMN form within the past 30 days before screening&#xD;
&#xD;
          -  History or presence of clinically significant acute or unstable hepatic, renal,&#xD;
             gastrointestinal, pulmonary, immunological, endocrine, diabetes, hematological or&#xD;
             oncological that in the opinion of the investigator would pose a significant risk for&#xD;
             the subject&#xD;
&#xD;
          -  Subject has untreated primary adrenal insufficiency based on morning plasma cortisol&#xD;
             and ACTH at screening&#xD;
&#xD;
          -  Lorenzo's Oil. Currently taking Lorenzo's Oil or erucic acid containing product, or&#xD;
             other lipid lowering agent known to effect VLCFA levels&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marianne Mancini</last_name>
    <phone>858-704-4674</phone>
    <email>mmancini@vikingtherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Becky Steele</last_name>
    <phone>858-704-4687</phone>
    <email>rsteele@vikingtherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Viking Clinical Site 203</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viking Clinical Site 207</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viking Clinical Site 201</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viking Clinical Site 206</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viking Clinical Site 205</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 28, 2021</study_first_submitted>
  <study_first_submitted_qc>July 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMN, XALD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenoleukodystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

